$CYTK
CYTOKINETICS INC

2020 Form 10-K Financial Statement

#000156459021009467 Filed on February 26, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $55.83M $5.210M $26.87M
YoY Change 107.79% -44.46% -14.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $52.80M $10.58M $39.60M
YoY Change 33.33% 39.95% 26.52%
% of Gross Profit
Research & Development $96.95M $18.33M $86.13M
YoY Change 12.57% -21.26% -3.38%
% of Gross Profit
Depreciation & Amortization $1.831M $390.0K $1.293M
YoY Change 41.61% -221.88% 4.36%
% of Gross Profit
Operating Expenses $149.8M $28.92M $125.7M
YoY Change 19.12% -6.23% 4.42%
Operating Profit -$93.94M -$98.87M
YoY Change -4.98% 11.19%
Interest Expense $15.96M -$6.930M $6.623M
YoY Change 141.02% 38.32% 74.43%
% of Operating Profit
Other Income/Expense, Net $5.329M $4.535M
YoY Change 17.51% 8.21%
Pretax Income -$127.3M -$30.64M -$121.7M
YoY Change 4.6% 15.75% 14.5%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$127.3M -$30.64M -$121.7M
YoY Change 4.6% 15.75% 14.49%
Net Earnings / Revenue -228.0% -588.1% -452.93%
Basic Earnings Per Share -$1.97
Diluted Earnings Per Share -$1.974M -$518.0K -$2.113M
COMMON SHARES
Basic Shares Outstanding 64.52K 59.08M
Diluted Shares Outstanding 64.52K

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $464.1M $225.1M $225.1M
YoY Change 106.18% 13.27% 13.29%
Cash & Equivalents $83.00M $36.43M $36.40M
Short-Term Investments $381.1M $188.7M $188.7M
Other Short-Term Assets $5.700M $3.500M $3.500M
YoY Change 62.86% 59.09% 59.09%
Inventory
Prepaid Expenses
Receivables $4.400M $5.163M $5.200M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $474.2M $233.8M $233.8M
YoY Change 102.82% 12.56% 12.57%
LONG-TERM ASSETS
Property, Plant & Equipment $22.60M $4.530M $13.40M
YoY Change 68.66% 41.39% 318.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $37.00M $42.70M $42.70M
YoY Change -13.35%
Other Assets
YoY Change
Total Long-Term Assets $59.60M $56.06M $56.00M
YoY Change 6.43% 1499.94% 1500.0%
TOTAL ASSETS
Total Short-Term Assets $474.2M $233.8M $233.8M
Total Long-Term Assets $59.60M $56.06M $56.00M
Total Assets $533.8M $289.8M $289.8M
YoY Change 84.2% 37.24% 37.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.100M $8.160M $8.200M
YoY Change -1.22% 116.79% 115.79%
Accrued Expenses $22.10M $12.12M $16.70M
YoY Change 32.34% -23.06% 5.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $31.20M $26.02M $26.00M
YoY Change 20.0% 17.25% 17.12%
LONG-TERM LIABILITIES
Long-Term Debt $135.7M $45.05M $129.3M
YoY Change 4.95% 13.18% 224.87%
Other Long-Term Liabilities $253.5M $145.5M $145.5M
YoY Change 74.23% 18771.6% 18.1%
Total Long-Term Liabilities $389.2M $45.05M $274.8M
YoY Change 41.63% 11.03% 68.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.20M $26.02M $26.00M
Total Long-Term Liabilities $389.2M $45.05M $274.8M
Total Liabilities $420.4M $300.8M $300.8M
YoY Change 39.76% 62.35% 62.42%
SHAREHOLDERS EQUITY
Retained Earnings -$865.0M
YoY Change 16.37%
Common Stock $853.4M
YoY Change 11.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $113.4M -$10.94M -$10.90M
YoY Change
Total Liabilities & Shareholders Equity $533.8M $289.8M $289.8M
YoY Change 84.2% 37.24% 37.22%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$127.3M -$30.64M -$121.7M
YoY Change 4.6% 15.75% 14.49%
Depreciation, Depletion And Amortization $1.831M $390.0K $1.293M
YoY Change 41.61% -221.88% 4.36%
Cash From Operating Activities $8.943M -$19.06M -$90.91M
YoY Change -109.84% 54.58% -10.18%
INVESTING ACTIVITIES
Capital Expenditures $11.05M -$1.310M $2.619M
YoY Change 321.99% 523.81% 194.6%
Acquisitions
YoY Change
Other Investing Activities -$185.5M -$104.0M -$72.09M
YoY Change 157.26% -489.07% -1297.51%
Cash From Investing Activities -$196.5M -$105.3M -$74.71M
YoY Change 163.05% -497.1% -1555.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $36.21M
YoY Change -100.0%
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities 234.1M 121.1M 159.8M
YoY Change 46.52% 26815.56% 1116.81%
NET CHANGE
Cash From Operating Activities 8.943M -19.06M -90.91M
Cash From Investing Activities -196.5M -105.3M -74.71M
Cash From Financing Activities 234.1M 121.1M 159.8M
Net Change In Cash 46.55M -3.210M -5.823M
YoY Change -899.45% -121.94% -92.98%
FREE CASH FLOW
Cash From Operating Activities $8.943M -$19.06M -$90.91M
Capital Expenditures $11.05M -$1.310M $2.619M
Free Cash Flow -$2.109M -$17.75M -$93.53M
YoY Change -97.75% 46.45% -8.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36433000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
188679000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5163000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5741000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
474221000
CY2020Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
36954000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020Q4 cytk Long Term Lease And Other Non Current Liabilities
LongTermLeaseAndOtherNonCurrentLiabilities
440000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13346000
CY2020Q4 cytk Operating Lease Right Of Use Assets And Other Assets
OperatingLeaseRightOfUseAssetsAndOtherAssets
9282000
CY2020Q4 us-gaap Assets
Assets
533803000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8050000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19315000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4616000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1124000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26023000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
45052000
CY2019Q4 cytk Convertible Notes Net
ConvertibleNotesNet
84205000
CY2019Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
143276000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2019Q4 cytk Long Term Lease And Other Non Current Liabilities
LongTermLeaseAndOtherNonCurrentLiabilities
2195000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71015183
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71015183
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55828000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26868000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31501000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96951000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86125000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
89135000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52820000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39610000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31282000
CY2020 us-gaap Operating Expenses
OperatingExpenses
149771000
CY2019 us-gaap Operating Expenses
OperatingExpenses
125735000
CY2018 us-gaap Operating Expenses
OperatingExpenses
120417000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-93943000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-121692000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.97
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.11
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.95
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
64524
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57575
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54420
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
179000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-106132000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-98867000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-88916000
CY2020 us-gaap Interest Expense
InterestExpense
15963000
CY2019 us-gaap Interest Expense
InterestExpense
6623000
CY2018 us-gaap Interest Expense
InterestExpense
3797000
CY2020 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
22713000
CY2019 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
20737000
CY2018 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
17767000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5329000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4535000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4191000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-127290000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-106289000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-530000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127820000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-121513000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
109842000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3173000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
928000
CY2018 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
866000
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
182000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9761000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
157000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-106289000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
25934000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1017000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1108000
CY2019 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
732000
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
185000
CY2019 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
49477000
CY2019 cytk Adjustments To Additional Paid In Capital Capped Call Options Associated With Convertible Notes
AdjustmentsToAdditionalPaidInCapitalCappedCallOptionsAssociatedWithConvertibleNotes
13386000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10759000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
179000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-121692000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-10937000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2020 cytk Adjustment To Additional Paid In Capital To Section16 B Claim Settlement
AdjustmentToAdditionalPaidInCapitalToSection16BClaimSettlement
2151000
CY2020 cytk Stock Issue During Period Private Placement Value
StockIssueDuringPeriodPrivatePlacementValue
36437000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1509000
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2255000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
184000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17620000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-530000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-127290000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113383000
CY2020 us-gaap Profit Loss
ProfitLoss
-127290000
CY2019 us-gaap Profit Loss
ProfitLoss
-121692000
CY2018 us-gaap Profit Loss
ProfitLoss
-106289000
CY2020 cytk Non Cash Interest Expense Related To Sale Of Future Royalties
NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
22792000
CY2019 cytk Non Cash Interest Expense Related To Sale Of Future Royalties
NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
20737000
CY2018 cytk Non Cash Interest Expense Related To Sale Of Future Royalties
NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
17767000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
17620000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
10759000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
9761000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1831000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1293000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1239000
CY2020 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
573000
CY2019 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2018 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2020 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-1194000
CY2019 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-2587000
CY2018 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-1677000
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
6640000
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
919000
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
920000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-743000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2932000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1119000
CY2020 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0
CY2019 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-4554000
CY2018 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-5154000
CY2020 cytk Increase Decrease In Prepaid And Other Current Assets
IncreaseDecreaseInPrepaidAndOtherCurrentAssets
2183000
CY2019 cytk Increase Decrease In Prepaid And Other Current Assets
IncreaseDecreaseInPrepaidAndOtherCurrentAssets
3862000
CY2018 cytk Increase Decrease In Prepaid And Other Current Assets
IncreaseDecreaseInPrepaidAndOtherCurrentAssets
-1817000
CY2020 cytk Increase Decrease In Operating Lease Right Of Use Assets And Other Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndOtherAssets
-1242000
CY2019 cytk Increase Decrease In Operating Lease Right Of Use Assets And Other Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndOtherAssets
-3552000
CY2018 cytk Increase Decrease In Operating Lease Right Of Use Assets And Other Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndOtherAssets
0
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-110000
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4396000
CY2018 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1490000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7117000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2168000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2063000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-18750000
CY2020 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4692000
CY2019 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3876000
CY2018 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
0
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
87000000
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6485000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8943000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90907000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-101215000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
435825000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
277883000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
240224000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
247301000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
202599000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
246232000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3061000
CY2019 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3196000
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11052000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2619000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
889000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
14000
CY2018 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
9898000
CY2020 cytk Proceeds From Convertible Notes Net Of Debt Discount And Issuance Costs
ProceedsFromConvertibleNotesNetOfDebtDiscountAndIssuanceCosts
0
CY2019 cytk Proceeds From Convertible Notes Net Of Debt Discount And Issuance Costs
ProceedsFromConvertibleNotesNetOfDebtDiscountAndIssuanceCosts
133860000
CY2018 cytk Proceeds From Convertible Notes Net Of Debt Discount And Issuance Costs
ProceedsFromConvertibleNotesNetOfDebtDiscountAndIssuanceCosts
0
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
36214000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-196515000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74707000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5133000
CY2020 cytk Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net
ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet
188883000
CY2019 cytk Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net
ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet
0
CY2018 cytk Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net
ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet
0
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
36225000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2018 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1509000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5356000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1393000
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3234000
CY2020 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
2151000
CY2019 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
0
CY2018 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
0
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2020 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
0
CY2019 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
13386000
CY2018 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
0
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
234124000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
159791000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13132000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46552000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5823000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-82950000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36433000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42256000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125206000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
82985000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36433000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42256000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
9620000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
4059000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
2877000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1106000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10687000
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-992300000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-127300000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8900000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
501000000.0
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
267800000
CY2020 cytk Cash Requirements Term
CashRequirementsTerm
P12M
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, investments, and accounts receivable.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash, cash equivalents and investments are invested in deposits with two major financial institutions in the United States. Deposits in these banks may exceed the amount of insurance provided on such deposits. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our exposure to credit risk associated with non-payment is limited to our strategic partners Amgen Inc. (“Amgen”)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Astellas Pharma Inc. (“Astellas”) </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ji Xing Pharmaceuticals Limited</span><span style="Background-color:#FFFFFF;color:#000000;"> (“Ji Xing”) </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and any material non-payment from our partners would result in a material breach of the agreements underlying our strategic partnerships. </span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug candidates we develop may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies prior to commercial sales. There can be no assurance that our drug candidates will receive any of the required approvals or clearances. If we were to be denied approval, or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p>
CY2020Q4 cytk Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
10700000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9600000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26362000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25465000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6246000
CY2019Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
45100000
CY2020Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
638700
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020 cytk Milestone Payments Received Under Arrangements
MilestonePaymentsReceivedUnderArrangements
2500000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
5300000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
4500000
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
1000000.0
CY2019 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
300000
CY2020 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2019 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2020Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
46200000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37987000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28725000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24641000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24195000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13346000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4530000
CY2020 us-gaap Depreciation
Depreciation
1800000
CY2019 us-gaap Depreciation
Depreciation
1300000
CY2020Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
6124000
CY2019Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
2215000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11787000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8343000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1404000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1565000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19315000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12123000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
900000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
600000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
5100000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
5000000.0
CY2019 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
13400000
CY2019Q4 cytk Capped Call Transactions Cap Price
CappedCallTransactionsCapPrice
14.07
CY2019Q4 cytk Capped Call Premium Percentage Of Sale Price Of Common Stock
CappedCallPremiumPercentageOfSalePriceOfCommonStock
0.70
CY2019Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
143276000
CY2018Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
122473000
CY2020 cytk Interest Accretion
InterestAccretion
22713000
CY2019 cytk Interest Accretion
InterestAccretion
20737000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
79000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
66000
CY2020Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
166068000
CY2019Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
143276000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6454037
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.72
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1785673
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.41
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.78
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
353905
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.44
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7759012
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.59
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1944562
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.59
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.27
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
234054
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.06
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8501949
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.02
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
91900000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5704396
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.91
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
67800000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
17231000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
153689000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
221072000
CY2020Q4 cytk Operating Leases Undiscounted Lease Payments1
OperatingLeasesUndiscountedLeasePayments1
217667000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
180000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3225000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4600000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12700000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17620000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10759000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9761000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.76
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
23065
CY2020 cytk Warrant Expiration Period
WarrantExpirationPeriod
2029-05
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
165424
CY2020Q4 cytk Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
7.25
CY2020 cytk Expiry Period Of Warrants After Date Of Issuance
ExpiryPeriodOfWarrantsAfterDateOfIssuance
P10Y
CY2020 cytk Sales Commission As Percentage Of Gross Proceeds
SalesCommissionAsPercentageOfGrossProceeds
0.030
CY2020Q1 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
2200000
CY2020 cytk Lease Expiration Year
LeaseExpirationYear
2021
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4616000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12694000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16194000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16648000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16200000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
6700000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
5000000.0
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
5700000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.03
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.02
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.04
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.04
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.23
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.30
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.17
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
162514000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
143228000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
71976000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
67892000
CY2020Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
36989000
CY2019Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
35213000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
10876000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
8690000
CY2020Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
2370000
CY2019Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
3949000
CY2020Q4 cytk Deferred Tax Assets Long Term Lease Liability
DeferredTaxAssetsLongTermLeaseLiability
718000
CY2019Q4 cytk Deferred Tax Assets Long Term Lease Liability
DeferredTaxAssetsLongTermLeaseLiability
1674000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
746000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
722000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
58000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
286189000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
261426000
CY2020Q4 cytk Deferred Tax Liabilities Accounting Method Change
DeferredTaxLiabilitiesAccountingMethodChange
927000
CY2019Q4 cytk Deferred Tax Liabilities Accounting Method Change
DeferredTaxLiabilitiesAccountingMethodChange
2047000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
651000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1484000
CY2020Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
9832000
CY2019Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
12011000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
11410000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
15542000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
274779000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
245884000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
28900000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
24800000
CY2020 cytk Research And Development Federal Tax Credit Carryforwards Expiration Date Year
ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear
2021
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9922000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9475000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9365000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
3000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
603000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
447000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
110000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10522000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9922000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9475000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
9600000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
9100000
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
8600000

Files In Submission

Name View Source Status
0001564590-21-009467-index-headers.html Edgar Link pending
0001564590-21-009467-index.html Edgar Link pending
0001564590-21-009467.txt Edgar Link pending
0001564590-21-009467-xbrl.zip Edgar Link pending
cytk-10k_20201231.htm Edgar Link pending
cytk-10k_20201231_htm.xml Edgar Link completed
cytk-20201231.xsd Edgar Link pending
cytk-20201231_cal.xml Edgar Link unprocessable
cytk-20201231_def.xml Edgar Link unprocessable
cytk-20201231_lab.xml Edgar Link unprocessable
cytk-20201231_pre.xml Edgar Link unprocessable
cytk-ex1059_198.htm Edgar Link pending
cytk-ex1060_197.htm Edgar Link pending
cytk-ex1061_196.htm Edgar Link pending
cytk-ex231_8.htm Edgar Link pending
cytk-ex311_10.htm Edgar Link pending
cytk-ex312_6.htm Edgar Link pending
cytk-ex313_9.htm Edgar Link pending
cytk-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gcktebo2xbkn000001.jpg Edgar Link pending
gzkc0wovp34b000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending